List of Aubagio drug patents
Aubagio is owned by Sanofi Aventis Us.
Aubagio contains Teriflunomide.
Aubagio has a total of 6 drug patents out of which 0 drug patents have expired.
Aubagio was authorised for market use on 12 September, 2012.
Aubagio is available in tablet;oral dosage forms.
Aubagio can be used as treatment of patients with relapsing forms of multiple sclerosis, treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose.
The generics of Aubagio are possible to be released after 04 August, 2034.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(3 years from now) | |
|
US6794410
(Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(4 years from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(7 years from now) | |
|
US8802735
(Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(8 years from now) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(11 years from now) | |
|
US9186346
(Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Apr 30, 2024 |
| Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic